Oxford Genetics, a UK-based developer of innovative synthetic biology-based technologies for biologics discovery, development and delivery, received a £7.5m investment.
Backers included existing investor Mercia Technologies and Invesco Perpetual.
The company intends to use the funds to open a new office in Boston, US and extend its UK facility at the Oxford Science Park by November 2017, which includes cell line engineering capabilities, viral vector production and purification suites, high-throughput robotic screening systems and process development facilities, invest in its research and development capabilities to increase its intellectual property (IP) portfolio and grow its of technology-enabled licensing business.
Led by Ryan Cawood, CEO, Oxford Genetics is a UK based biotechnology company specializing in the production of versatile cloning plasmids for research in academic and biotechnology institutions. The company also provides custom cloning and DNA synthesis.
During the latest year, the company has increased the number of clients, key appointments, and market momentum in the growth areas of cell and gene therapy. It has also signed a number of licenses for use of its technologies, including two collaborative partnerships with gene therapy companies designed to develop its IP offering further, as well as filing five new patents intended to improve the discovery, development or delivery of biotherapeutics.